Evidence map›Paper›PMID 34183723›Full record

ArticleScientific reports2021

Soluble cluster of differentiation 14 levels elevated in bile from gallbladder cancer cases from Shanghai, China.

Victoria L Brun, Amanda F Corbel, Ann W Hsing, Troy J Kemp, Alison L Van Dyke, Allan Hildesheim, Bin Zhu, Yu-Tang Gao, Ligia A Pinto, Jill Koshiol

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Victoria L BrunPartnership Development Office, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. victoria.brun@nih.gov.
Amanda F CorbelPartnership Development Office, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Ann W HsingStanford Prevention Research Center/Cancer Institute, Stanford University, Stanford, CA, USA.
Troy J KempVaccine, Immunity and Cancer Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Alison L Van DykeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Allan HildesheimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Bin ZhuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Yu-Tang GaoDepartment of Epidemiology, Shanghai Cancer Institute, Shanghai, China.
Ligia A PintoVaccine, Immunity and Cancer Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USDivision of Cancer Epidemiology and GeneticsShanghai Cancer Institute · CNStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated systemic levels of soluble cluster of differentiation 14 (sCD14) have been associated with gallbladder cancer (GBC), but the association with sCD14 levels within the gallbladder has not been investigated. Here, we evaluated sCD14 in the bile of 41 GBC cases and 117 gallstone controls with data on 65 bile inflammation markers. We examined the relationship between bile sCD14 levels and GBC using logistic regression and stratified the analysis by stage. We included GBC-associated inflammatory biomarkers in the model to evaluate the influence of local inflammation. Bile sCD14 levels (third versus first tertile) were associated with GBC (adjusted odds ratio [OR]: 3.0, 95% confidence interval [CI]: 1.2-8.0). The association was equally strong for stage I/II (OR: 3.3, 95% CI: 0.9-15.6) and stage III/IV (OR: 3.2, 95% CI: 1.0-12.4) cancers. Including the GBC-associated inflammatory markers in the model removed the association between bile sCD14 and GBC (OR: 1.0, 95% CI: 0.3-3.5). The findings suggest that immune activation within the gallbladder may be related to GBC development, and the effect of sCD14 is influenced by inflammation. Similar associations across tumor stages suggest that elevated bile sCD14 levels may reflect changes early in GBC pathogenesis. Associations between GBC and sCD14 levels in both bile and plasma suggest sCD14 could be a potential biomarker for GBC.

Indexed as

AdultAgedAlcohol DrinkingAntigens, NeoplasmBileBiomarkersCarcinomaChinaCholelithiasisCigarette SmokingComorbidityDiabetes MellitusEducational StatusFemaleGallbladder NeoplasmsHumansAntigens, NeoplasmBiomarkersLipopolysaccharide Receptors

Identifiers

PMID34183723
PMCPMC8239000
OpenAlexW3176745293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.